Agents targeting inflammation in heart failure

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 557-566

  Gullestad, Lars ^a   Kjekshus, John ^a   Damås, Jan Kristian ^a   Ueland, Thor ^a   Yndestad, Arne ^a   Aukrust, Pål ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytokines; Heart failure; Inflammation; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CHEMOKINE; CARDIOTROPHIN 1; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETANERCEPT; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METOPROLOL; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIPERANOMETOZINE; PLACEBO; ROSUVASTATIN; SPIRONOLACTONE; THALIDOMIDE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPOTHESIS; IMMUNOMODULATION; IMMUNOSTIMULATION; LEUKOCYTE; META ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; RAT; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION MEDIATORS;

EID: 20344365308     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.557     Document Type: Review

References (100)

1. STEWART S, MacINTYRE K, MacLEOD MMC, BAILEY AM, CAPWELL S, McMURRAY JJ: Trends in hospitalization for heart failure in Scotland, 1990-1996. Eur. Heart J. (2001) 22:209-217.
2. COWIE MR, MOSTERD A, WOOD DA et al.: The epidemiology of heart failure. Eur. Heart J. (1997) 18:208-225.
3. LEVINE B, KALMAN J, MAYER L, FILLIT HM, PACKER M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. (1990) 323:236-241.
4. AUKRUST P, UELAND T, LIEN E et al.: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1999) 83:376-382.
5. TESTA M, YEH M, LEE P et al.: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. (1996) 28:964-971.
6. TORRE-AMIONE G, KAPADIA S, BENEDICT C, ORAL H, YOUNG JB, MANN DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27:1201-1206.
7. KAWAKAMI H, SHIGEMATSU Y, OHTSUKA T: Increased circulating soluble form of Fas in patients with dilated cardiomyopathy. Jpn. Circ. J. (1998) 62:873-876.
8. MATSUMORI A, YAMADA T, SUZUKI H, MATOBA Y, SASAYAMA S: Increased levels of cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. (1994) 72:561-566.
9. SHIOI T, MATSUMORI A, KIHARA Y et al.: Increased expression of interleukin-1β and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ. Res. (1997) 81:644-671.
10. AUKRUST P, UELAND T, MULLER F et al.: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 97:1136-1143.
11. DAMÅS JK, GULLESTAD L, UELAND T et al.: CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc.Res. (2000) 45:428-436.
12. DAMÅS JK, GULLESTAD L, AASS H et al.: Enhanced gene expression of chemockines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effects of intravenous immunoglobulin. J. Am. Coll. Cardiol. (2001) 38:187-193.
13. DEVEAUX B, SCHOLZ D, HIRCHE A, KLØVERKORN WP, SCHAPER J: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur. Heart J. (1997) 18:470-479.
14. DAMÅS JK, EIKEN HG, ØIE E et al.: Myocardial expression of CC- and CXC- chemokines and their receptors in human end-stage heart failure. Cardiovasc. Res. (2000) 47:778-787.
15. KAPADIA S: Cytokines and heart failure. Cardiol. Rev. (1999) 7:196-206.
16. SETA Y, SHAN K, BOZKURT B, ORAL H, MANN DL: Basic mechanism in heart failure: the cytokine hypothesis. J. Cardiac Failure (1996) 2:243-249.
17. DESWAL A, PETERSEN NJ, FELDMAN AM, YOUNG JB, WHITE BG, MANN DL: Cytokines and cytokine receptors in advanced heart failure. Circulation (2001) 103:2055-2059.
18. NATANSON C, EICHENHOLZ PW, DANNER RL et al.: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. (1989) 169(3):823-832.
19. KUBOTA T, McTERNAN CF, FRYE CS et al.: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexspression of tumor necrosis factor-α. Circ. Res. (1997) 81:627-635.
20. BOZKURT B, KRIBBS SB, CLUBB FJ et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive dysfunction and remodelling in rats. Circulation (1998) 97:1382-1391.
21. KUNISADA K, HIROTA H, FUJIO Y et al.: Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation (1996) 94:2626-2632.
22. HIROTA H, CHEN J, BETZ AK et al.: Loss of gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 97:189-198.
23. SASAYAMA S, OKADA M, MATSUMORI A: Chemokines and cardiovascular diseases. Cardiovasc. Res. (2000) 45:267-269.
24. KOLATTUKUDY PE, QUASCH T, BERGES S: Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am. J. Pathol. (1998) 152:101-111.
25. COOK DN, BECK MA, COFFMAN TM et al.: Requirement of MIP-1α lot for an inflammatory response to viral infection. Science (1995) 269:1583-1585.
26. TACHIBANA K, HIROTA S, ILZASA H et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 393:524-525.
27. NAITO Y, TSUJINO T, FUJIOKA Y, OHYANAGI M, OKAMURA H, IWASAKI T: Increased circulating interleukin-18 in patients with congestive heart failure. Heart (2002) 88(3):296-297.
28. WOLDBAEK PR, TONNESSEN T, HENRIKSEN UL et al.: Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. (203) 59(1):122-131.
29. YNDESTAD A, UELAND T, ØIE E et al.: Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation (2004) 109:1379-1385.
30. YNDESTAD A, DAMÅS JK, EIKEN HG et al.: Increased gene expression of TNF superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc. Res. (2002) 54:175-182.
31. YNDESTAD A, HOLM AM, MULLER F et al.: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc. Res. (2003) 60:141-146.
32. UELAND T, YNDESTAD A, ØIE E et al.: Dysregulated osteopotegrin/RANK-ligand/RANK axis in clinical and experimental heart failure. Circulation (2005) (In Press).
33. UELAND T, JEMTLAND R, GODANG K et al.: Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. Coll. Cardiol. (2004) 44:1970-1976.
34. WALSH MC, CHOI Y: Biology of the TRANCE axis. Cytokine Growth Factor Rev. (2003) 14(3-4):251-263.
35. YAMAMOTO K, SHIOI T, UCHIYAMA K, MIYAMOTO T, SASAYAMA S, MATSUMORI A: Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-κB activation in knockout mice. J. Am. Coll. Cardiol. (2003) 42(11):2000-2006.
36. GULLESTAD L, AUKRUST P, UELAND T et al.: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. (1999) 34:2061-2067.
37. SWEDBERG K, HELD P, KJEKSHUS J, RASMUSSEN K, RYDEN L, WEDEL H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. (1992) 327:678-684.
38. MAISEL AS: Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunological function. Circulation (1994) 90:1774-1780.
39. MAISEL AS, MURRAY D, LOTZ M, REARDEN A, IRWIN M, MICHEL MC: Propranolol treatment affects parameters of human immunity. Immunopharmacol. (1991) 22:157-164.
40. HARAGUCHI S, GOOD RA, DAY NK: Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol. Today (1995) 16:595-603.
41. OHTSUKA T, HAMADA M, HIASA G et al.: Effects of β-blockers on circulating levels of inflammatory and antiinflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. (2001) 37:412-417.
42. GULLESTAD L, UELAND T, BRUNSVIG A et al.: Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the Metoprolol Controlled-Release Randomized Intervention Trial in Heart failure (MERIT-HF trial). Am. Heart J. (2001) 141:418-421.
43. TSUTAMOTO T, WADA A, MATSUMOTO T et al.: Relationship between tumor necrosis factor-α production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. (2001) 37:2086-2092.
44. YAMADA T, MATSUMORI A, SASAYAMA S: Therapeutic effect of antitumor necrosis factor-α on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation (1994) 89:846-851.
45. DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224-3226.
46. MANN DL, McMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-1602.
47. LISMAN KA, STETSON SJ, KOERNER T et al.: The role of tumor necrosis factor-α in the treatment of congestive heart failure. Congest. Heart Failure (2002) 8:275-279.
48. KADOKAMI T, McTIERNAN CF, KUBOTA T et al.: Effects of soluble TNF receptor treatment on lipopolysaccaride-induced myokardial cytokine expression. Am. J. Physiol. (2001) 280:H2281-H2291.
49. LUGERING A, SCHMIDT M, LUGERING N, PAUELS HG, DOMSCKE W: Infliximab induces apoptosis in myocytes from patients with chronic active Crohn's disease by using caspase-dependent pathway. Gastroenterology (2001) 121:1145-1157.
50. EVANS TJ, MOYES D, CARPENTER A et al.: Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J. Exp. Med. (1994) 180(6):2173-2179.
51. MELDRUM DR: Tumor necrosis factor in the heart. Am. J. Physiol. (1998) 274:R577-R595.
52. KEITH M, GERANMAYEGAN A, SOLE MJ et al.: Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol. (1998) 31:1352-1356.
53. SINGAL PK, KHAPER N, PALACE V, KUMAR D: The role of oxidative stress in the genesis of heart disease. J. Am. Coll. Cardiovasc.Res. (1998) 40:426-432.
54. KEITH ME, JEEJEEBHOY KN, LANGER A et al.: A controlled trial of vitamin E supplementation in patients with congestive heart failure. Am. J. Clin. Nutr. (2001) 73:219-224.
55. NOLAN Y, MINOGUE A, VEREKER E, BOLTON AE, CAMPBELL VA, LYNCH MA: Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy. Neuroimmunomodulation (2002) 10(1):40-46.
56. TORRE-AMIONE G, SESTIER F, RADOVANCEVIC B, YOUNG J: Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, Phase II trial. J. Am. Coll. Cardiol. (2004) 44(6):1181-1186.
57. SLIWA K, SKUDICKY D, CANDY G, WISENBAUGH T, SARELI P: Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet (1998) 351:1091-1093.
58. SKUDICKY D, BERGEMANN A, SLIWA K, CANDY G, SARELI P: Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation (2001) 103:1083-1088.
59. SLIWA K, WOODIWISS A, KONE VN et al.: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation (2004) 109(6):750-755.
60. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian simvastatin survival study (4S). Lancet (1995) 344:1383-1389.
61. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cqardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N. Engl. J. Med. (1998) 339:1349-1357.
62. KWAK B, MULHAUP F, MYLT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399-1402.
63. TAKEMOTO M, NODE K, NAKAGAMI H et al.: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. (2001) 108:1429-1437.
64. KRUM H, McMURRAY JJ: Statins and chronic heart failure: do we need a large scale outcome trial? J. Am. Coll. Cardiol. (2002) 39:1567-1573.
65. MULLER J, WALLUKAT G, DANDEL M et al.: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation (2000) 101:285-391.
66. STAUDT A, SCHAPER F, STANGL V et al.: Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation (2001) 103:2681-2686.
67. NISHIMURA H, OKAZAKI T, TANAKA Y et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 291(5502):319-322.
68. OKAZAKI T, TANAKA Y, NISHIO R et al.: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med.. (2003) 9(12):1477-1483.
69. BALLOW M: Mechanism of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J. Allergy Clin. Immunol. (1997) 100:151-157.
70. MOBINI N, SARELA A, AHMED AR: Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann. Allergy Asthma Immunol. (1995) 74:119-128.
71. McNAMARA DM, ROSENBLUM WD, JANOSKO KM et al.: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 95:2476-2478.
72. BOZKURT B, VILLANEUVA FS, HOLUBKOV R et al.: Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J. Am. Coll. Cardiol. (1999) 34:177-180.
73. GULLESTAD L, AASS H, FJELD JG et al.: Effect of immunomodulating therapy with intravenous immunglobulin in chronic congestive heart failure. Circulation (2001) 103:220-225.
74. McNAMARA DM, HOLUBKOV R, STARLING RC et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation (2001) 103:2254-2259.
75. VIARD I, WEHRLI P, SCHNEIDER P et al.: Inhibition of toxic necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 282:490-493.
76. WOLF HM, EIBL MM: Immunomodulatory effect of immunoglobulins. Clin. Exp. Rheumatol. (1996) 14(Suppl. 15):S17-S25.
77. AUKRUST P, GULLESTAD L, LAPPEGÅRD KT et al.: Complement activation in patients with congestive heart failure-effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 104:1494-1500.
78. NISHIO R, MATSUMORI A, SHIOI T, ISHIDA H, SASAYAMA S: Treatment of experimental viral myocarditis with interleukin-10. Circulation (1999) 100:1102-1108.
79. MALLAT Z, BESNARD S, DURIEZ M et al.: Protective role of interleukin-10 in atheroscleosis. Circ. Res. (1999) 85:17-24.
80. LODDICK SA, ROTHWELL NJ: Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood. Flow. Metab. (1996) 16:932-940.
81. UNGUREANU-LONGROIS D, BALLIGAND J-L, SIMMONS WW et al.: Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsivness to β-adrenergic agonists. Circ. Res. (1995) 77:494-502.
82. JACOBSEN JM: Thalidomide: a remarkable comeback. Expert Opin. Pharmacother. (2000) 1:849-863.
83. ADLARD JW. Thalidomide in the treatment of cancer. Anticancer Drugs (2000) 11:787-791.
84. SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. (1991) 173:699-703.
85. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. (1999) 163:380-386.
86. KEIFER JA, GUTTRIDGE DC, ASHBURNER AP, BALDWIN J: Inhibition of NF-κB activity by thalidomide throuh suppression of I κB kinase activity. J. Biol. Chem. (2001) 267:22382-22387.
87. ZORAT F, SHETTY V, DUTT D et al.: The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. (2001) 115:881-894.
88. BARLETT JB, MICHAEL A, CLARKE IA et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer (2004) 90:955-961.
89. GELATI M, CORSINI E, FRIGERIO S et al.: Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J. Neurooncol. (2003) 64:193-201.
90. ASAKAWA M, TAKANO H, NAGAI T et al.: Peroxisome, proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 105(10):1240-1246.
91. TIEDEMANN H, ASASHIMA M, GRUNZ H, KNOCHEL W: Pluripotent cells (stem cells) and their determination and differentiation in early vertebrate embryogenesis. Devel. Growth Diff. (2001) 43(5):469-502.
92. LIMAS CJ, HASIKIDIS C, IAKOVOU J, KROUPIS C, HAIDAROGLOU A, COKKINOS DV: Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur. J. Clin. Investig. (2003) 33(6):443-448.
93. GREEN JM: The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease. Am. J. Resp. Cell Mol. Biol. (2000) 22(3):261-264.
94. SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. (1919):225-252.
95. KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig. N. Engl. J. Med. (2003) 349(20):1907-1915.
96. HAYASHIDANI S, TSUTSUI H, SHIOMI T et al.: Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2003) 108(17):2134-2140.
97. SUZUKI K, MURTUZA B, SMOLENSKI RT et al.: Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation (2001) 104(12 Suppl. 1):1308-1313.
98. TAKANO H, NAGAI T, ASAKAWA M et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ. Res. (2000) 87(7):596-602.
99. HARA M, ONO K, HWANG MW et al.: Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. (2002) 195:375-381.
100. HOCHER B, GODES M, OLIVIER J et al.: Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J. Hypertension (2002) 20(4):745-751.